Zydus Lifesciences Limited , a global innovation-driven healthcare company, has announced a significant addition to its senior management team. The company's Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Nitin D. Parekh as President (Special Projects), effective September 8, 2025, for a two-year term.

Strengthening Management Amid Business Growth

The appointment comes as Zydus Lifesciences aims to reinforce its management team in response to the increasing size, scale, and complexity of its business operations. Parekh, a seasoned professional with over four decades of experience, is set to bring his extensive expertise to this newly created role.

A Stellar Professional Background

Nitin D. Parekh, aged 64, brings an impressive array of qualifications and experience to his new position:

• Educational Background: Chartered Accountant (CA), Chartered Financial Analyst (CFA), and MBA from the Indian Institute of Management, Ahmedabad
• Professional Experience: Over 40 years across finance, strategy, legal, and IT sectors, with a focus on pharmaceuticals and textiles
• Previous Role: Served as Chief Financial Officer at Zydus Lifesciences for more than 16 years

Award-Winning Finance Leader

Parekh's exceptional career is marked by numerous accolades, including:

• Best CFO of Healthcare & Pharma (2025) from Assocham
• Hall of Fame (2024) from CFO Collective
• Excellence in M&A from CII
• Best CFO of India-Large Enterprises from Businessworld (2021)
• Best CFO of Healthcare sector in India from ICAI (2012 and 2017)

Strategic Appointment for Future Growth

The appointment of Nitin D. Parekh as President (Special Projects) is a strategic move by Zydus Lifesciences to leverage his extensive experience in finance, strategy, and general management. His expertise in areas such as M&A, negotiations, deal structuring, and capital structure design is expected to play a crucial role in the company's future endeavors.

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited, confirmed the appointment in a regulatory filing, emphasizing the company's intent to strengthen its management team in view of its growing business operations and complexity.

As Zydus Lifesciences continues to expand its global footprint in the healthcare sector, the addition of Nitin D. Parekh to its senior management is poised to contribute significantly to the company's strategic initiatives and overall growth trajectory.

Zydus Lifesciences Ltd. , a global healthcare innovator, has announced a significant move in the U.S. pharmaceutical market. The company's wholly-owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for generic Ozanimod capsules, targeting the U.S. market.

Partnership Details

The agreement focuses on bringing a generic version of ZEPOSIA® (Ozanimod) to American consumers. Synthon, which has a pending abbreviated new drug application in the United States, will be responsible for obtaining final regulatory approval, manufacturing, and supplying the product. Zydus will take charge of commercializing the generic Ozanimod capsules in the USA.

Market Potential

This strategic partnership taps into a substantial market opportunity. According to IQVIA MAT July 2025 data, the total addressable market for Ozanimod Capsules in the U.S. is approximately $637.00 million.

Regulatory Status and Exclusivity

Synthon's position as one of the first filers for generic Ozanimod has secured them tentative approval from the U.S. Food and Drug Administration (FDA) within 30 months. This status makes the product eligible for a shared 180-day exclusivity upon market entry, potentially giving Zydus and Synthon a competitive edge in the generic Ozanimod market.

About Ozanimod

ZEPOSIA® (Ozanimod) is a sphingosine 1-phosphate receptor modulator with significant therapeutic applications. It is indicated for:

• Treatment of relapsing forms of multiple sclerosis (MS) in adults, including:
  • Clinically isolated syndrome
  • Relapsing-remitting disease
  • Active secondary progressive disease
• Treatment of moderately to severely active ulcerative colitis (UC) in adults

Executive Perspectives

Punit Patel, President and Chief Executive Officer of Zydus Pharmaceuticals (USA) Inc., emphasized the importance of this collaboration, stating, "This collaboration with Synthon enables us to bring this important treatment to the U.S. market. This collaboration reinforces our strategic focus on advancing care in therapeutic areas and reflects our commitment to making essential medicines more accessible to patients."

Anish Mehta, Chief Executive Officer of Synthon BV, added, "This collaboration with Zydus for Ozanimod capsules continues to underscore our proven expertise in developing first-to-market, complex generic products. We are pleased to strengthen our partnership with Zydus as we continue advancing our strategic commitment to expanding access to essential medicines."

Conclusion

This partnership between Zydus Lifesciences and Synthon represents a significant step in expanding access to generic versions of important medications in the U.S. market. By combining Synthon's expertise in developing complex generics with Zydus's strong commercialization capabilities, the companies aim to provide more affordable options for patients requiring Ozanimod treatment for multiple sclerosis and ulcerative colitis.